"Dean McGee Eye Institute's main location is on the campus of the Oklahoma Health Center. With a prominent location on the northeast corner of Lincoln Boulevard and NE 10th Street, DMEI OHC boasts 100 examination rooms on three floors along with complete diagnostic and imaging services. Thirty ophthalmologists and four optometrists practice at this location and provide a vast variety of eye care services, including adult and pediatric ophthalmology, LASIK, optometry, ophthalmic plastic & reconstructive surgery, glaucoma treatment, cornea & external disease treatment, ocular oncology, and more. DMEI OHC also hosts a full-service optical shop that carries the best in eyewear for both prescriptive and non-prescriptive needs."

During the past decade, Dean A McGee Eye Institute conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 19 clinical trials were completed, i.e. on average, 79.2% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 13 clinical trials were completed. i.e. 144.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dean A McGee Eye Institute" #1 sponsor was "Jaeb Center for Health Research" with 13 trials, followed by "University of Oklahoma" with 6 trials sponsored, "Bausch & Lomb Incorporated" with 2 trials sponsored, "Eyetech Pharmaceuticals" with 2 trials sponsored and "Genentech, Inc." with 2 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dean A McGee Eye Institute" #1 collaborator was "National Eye Institute (NEI)" with 14 trials as a collaborator, "Pediatric Eye Disease Investigator Group" with 5 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator, "Bayer" with 2 trials as a collaborator and "National Institutes of Health (NIH)" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Dean A McGee Eye Institute" are "Diabetic Macular Edema" (7 trials), "Diabetic Retinopathy" (6 trials), "Macular Degeneration" (5 trials), "Cataract" (4 trials) and "Primary Open Angle Glaucoma" (3 trials). Many other conditions were trialed in "Dean A McGee Eye Institute" in a lesser frequency.

Most popular intervention types in "Dean A McGee Eye Institute" are "Drug" (34 trials), "Device" (10 trials), "Procedure" (9 trials), "Other" (8 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Trabeculectomy" (3 trials), "Acetazolamide" (2 trials), "Lampalizumab" (2 trials) and "bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Dean A McGee Eye Institute" are 49 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Dean A McGee Eye Institute". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 35 completed trials in Dean A McGee Eye Institute, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Dean A McGee Eye Institute, 4 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 15 trials that are defined as “Not Applicable".